Advances in Small-molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-cancer Agents
Authors:
- 1 September 2025
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (25) , 5180-5225
Abstract
As members of the protein tyrosine kinase family, the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) play essential roles in cellular signal transduction pathways. Overexpression or abnormal activation of EGFR and HER2 can lead to the development of various solid tumors. Therefore, they have been confirmed as biological targets for the development of anticancer drugs. Due to the fact that many cancers are highly susceptible to develop resistance to single-target EGFR inhibitors in clinical practice, dual inhibitors that target both EGFR and HER2 have been developed to increase efficacy, reduce drug resistance and interactions, and improve patient compliance. Currently, a variety of EGFR/HER2 dual inhibitors have been developed, with several drugs already approved for marketing or in clinical trials. In this review, we summarize recent advancements in small-molecule EGFR/HER2 dual inhibitors by focusing on structure-activity relationships and share novel insights into developing anticancer agents.Keywords
This publication has 204 references indexed in Scilit:
- 2-substituted 4-aminoquinazoline derivatives as potential dual inhibitors of EGFR and HER2: an in silico and in vitro studyMedicinal Chemistry Research, 2022
- Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 studyCancer, 2021
- Synthetic strategies for pyrrolo[2,1-f][1,2,4]triazine: the parent moiety of antiviral drug remdesivirChemistry of Heterocyclic Compounds, 2020
- Pharmacophore modeling, 3D‐QSAR, synthesis, and anti‐lung cancer evaluation of novel thieno[2,3‐d][1,2,3]triazines targeting EGFRArchiv der Pharmazie, 2020
- Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2Journal of Computer-Aided Molecular Design, 2019
- Design and Synthesis of 4‐Anilinothieno[2,3‐d]pyrimidine‐Based Compounds as Dual EGFR/HER‐2 InhibitorsArchiv der Pharmazie, 2016
- A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cellsApoptosis, 2015
- Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2Investigational New Drugs, 2013
- Tea polyphenol (−)‐epigallocatechin‐3‐gallate inhibits nicotine‐ and estrogen‐induced α9‐nicotinic acetylcholine receptor upregulation in human breast cancer cellsMolecular Nutrition & Food Research, 2010
- The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in ratsInvestigational New Drugs, 2010